APPOINTMENTS: Apellis, Araim, Ascendis, Chronos, Intrexon and Proteostasis

Chrono Therapeutics Inc. has hired two ex-Shire PLC executives to lead clinical development for the recently acquired pipeline programs it picked up from the Irish pharma company. Meanwhile, Apellis Pharmaceuticals Inc., Ascendis Pharma A/S, Intrexon Corporation and Proteostasis Therapeutics Inc. have made senior appointments and Araim Pharmaceuticals has named a new chair for its board of directors.

Chrono Therapeutics Inc., a private biotech company focused on ageing diseases, brain and nervous system disorders, has named Drs. Fraser Murray and Timothy Schulz-Utermoehl vice presidents of pre-clinical development. The pair join Chronos from Polleo Pharma, a UK biotech start-up company they co-founded, and will be responsible for three preclinical research programs recently acquired by Chronos from Shire PLC – these include a dopamine active transporter inhibitor program in multiple sclerosis fatigue and the company's orexin 1 antagonist program in addictive behaviors. Both Murray and Schulz-Utermoehl have previously held leadership roles at Shire plc, AstraZeneca PLC and Merck & Co. Inc. Prior to founding Polleo Pharma Murray was senior director and head of discovery biology for Shire Speciality Pharmaceuticals; and Schulz-Utermoehl was a director within the exploratory projects department for Shire.

Apellis Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds for the treatment of autoimmune...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Executives On The Move

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Executives On The Move: New CEOs At Sun Pharma And TME Pharma

Recent moves in the industry include C-suite changes at Abvance Therapeutics, plus Galapagos gets new chief financial officer from Horizon Therapeutics.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.

More from Leadership

Executives On The Move: New CEOs At Sun Pharma And TME Pharma

Recent moves in the industry include C-suite changes at Abvance Therapeutics, plus Galapagos gets new chief financial officer from Horizon Therapeutics.

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.

Watch This Space: Miltenyi‘s ‘Brain-To-Vein,’ Point-Of-Care CAR-T Efforts In India

 

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.